Skip to content

ALPINE IMMUNE SCIENCES, INC.

Delisted

CIK 1626199fmd_1C14SAXQHPMVKWZ8243MERB752Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2013 to Mar 31, 2024, 42 periods

Latest annual · FY2023

Millions
Total revenues
59
Operating income
(44)
Net income
(32)
Free cash flow
(79)

Latest quarter · Q1 FY2024

Millions
Total revenues
7
Operating income
(23)
Net income
(18)
Free cash flow
(28)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2020 to FY2023
+84.8%
Revenue, 5 yearsFY2018 to FY2023
+142.3%
Net income, 5 yearsFY2018 to FY2023
n/m

ALPINE IMMUNE SCIENCES, INC. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2023FY2022ChangeSource
Revenue$58.9 million$30.1 million+95.8%10-K 2024-03-20 · proof
Operating income-$44.3 million-$58.1 million10-K 2024-03-20 · proof
Net income-$32.2 million-$57.8 million10-K 2024-03-20 · proof
Cash from operating activities-$79 million-$43.8 million10-K 2024-03-20 · proof
Free cash flow-$79.5 million-$44.2 million10-K 2024-03-20 · proof
Total assets$379.9 million$286.7 million+32.5%10-K 2024-03-20 · proof
Total liabilities$51.9 million$107.3 million-51.6%10-K 2024-03-20 · proof
Cash and cash equivalents$43.9 million$13.4 million+228.4%10-K 2024-03-20 · proof
What was ALPINE IMMUNE SCIENCES, INC.'s revenue in fiscal 2023?
ALPINE IMMUNE SCIENCES, INC. reported revenue of $58.9 million for fiscal 2023 (the year ended Dec 31, 2023), against $30.1 million the year before (+95.8%). Source: the 10-K filed with the SEC on Mar 20, 2024. SEC
What was ALPINE IMMUNE SCIENCES, INC.'s operating income in fiscal 2023?
ALPINE IMMUNE SCIENCES, INC. reported operating income of -$44.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$58.1 million the year before. Source: the 10-K filed with the SEC on Mar 20, 2024. SEC
What was ALPINE IMMUNE SCIENCES, INC.'s net income in fiscal 2023?
ALPINE IMMUNE SCIENCES, INC. reported net income of -$32.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -$57.8 million the year before. Source: the 10-K filed with the SEC on Mar 20, 2024. SEC
What was ALPINE IMMUNE SCIENCES, INC.'s cash from operating activities in fiscal 2023?
ALPINE IMMUNE SCIENCES, INC. reported cash from operating activities of -$79 million for fiscal 2023 (the year ended Dec 31, 2023), against -$43.8 million the year before. Source: the 10-K filed with the SEC on Mar 20, 2024. SEC
What was ALPINE IMMUNE SCIENCES, INC.'s free cash flow in fiscal 2023?
ALPINE IMMUNE SCIENCES, INC. reported free cash flow of -$79.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$44.2 million the year before. Source: the 10-K filed with the SEC on Mar 20, 2024. SEC
What are ALPINE IMMUNE SCIENCES, INC.'s total assets?
As of Dec 31, 2023, ALPINE IMMUNE SCIENCES, INC. reported total assets of $379.9 million, against $286.7 million a year earlier (+32.5%). Source: the 10-K filed with the SEC on Mar 20, 2024. SEC
What are ALPINE IMMUNE SCIENCES, INC.'s total liabilities?
As of Dec 31, 2023, ALPINE IMMUNE SCIENCES, INC. reported total liabilities of $51.9 million, against $107.3 million a year earlier (-51.6%). Source: the 10-K filed with the SEC on Mar 20, 2024. SEC
What are ALPINE IMMUNE SCIENCES, INC.'s cash and cash equivalents?
As of Dec 31, 2023, ALPINE IMMUNE SCIENCES, INC. reported cash and cash equivalents of $43.9 million, against $13.4 million a year earlier (+228.4%). Source: the 10-K filed with the SEC on Mar 20, 2024. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1626199&period_type=annual&limit=5"

Information only, not investment advice.